Switch to: References

Add citations

You must login to add citations.
  1. Appraising Harm in Phase I Trials: Healthy Volunteers' Accounts of Adverse Events.Lisa McManus, Arlene Davis, Rebecca L. Forcier & Jill A. Fisher - 2019 - Journal of Law, Medicine and Ethics 47 (2):323-333.
    While risk of harm is an important focus for whether clinical research on humans can and should proceed, there is uncertainty about what constitutes harm to a trial participant. In Phase I trials on healthy volunteers, the purpose of the research is to document and measure safety concerns associated with investigational drugs, and participants are financially compensated for their enrollment in these studies. In this article, we investigate how characterizations of harm are narrated by healthy volunteers in the context of (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • Paying for Fairness? Incentives and Fair Subject Selection.Douglas MacKay & Rebecca L. Walker - 2021 - American Journal of Bioethics 21 (3):35-37.
    In their Target Article, “Promoting Ethical Payment in Human Infection Challenge Studies,” Lynch et al. propose a framework for ethical payment to research participants and apply it to the c...
    Download  
     
    Export citation  
     
    Bookmark   3 citations  
  • Promoting Ethical Payment in Human Infection Challenge Studies.Holly Fernandez Lynch, Thomas C. Darton, Jae Levy, Frank McCormick, Ubaka Ogbogu, Ruth O. Payne, Alvin E. Roth, Akilah Jefferson Shah, Thomas Smiley & Emily A. Largent - 2021 - American Journal of Bioethics 21 (3):11-31.
    To prepare for potential human infection challenge studies involving SARS-CoV-2, we convened a multidisciplinary working group to address ethical questions regarding whether and how much SAR...
    Download  
     
    Export citation  
     
    Bookmark   18 citations  
  • Risky first-in-human clinical trials on medically fragile persons: owning the moral cost.Christopher Bobier - 2024 - Theoretical Medicine and Bioethics 45 (6):447-459.
    The purpose of a first-in-human (FIH) clinical trial is to gather information about how the drug or device affects and interacts with the human body: its safety, side effects, and (potential) dosage. As such, the primary goal of a FIH trial is not participant benefit but to gain knowledge of drug or device efficacy, i.e., baseline human safety knowledge. Some FIH clinical trials carry _significant_ foreseeable risk to participants with little to no foreseeable participant benefit. Participation in such trials would (...)
    Download  
     
    Export citation  
     
    Bookmark  
  • To report or not to report: Exploring healthy volunteers' rationales for disclosing adverse events in Phase I drug trials.Lisa McManus & Jill A. Fisher - 2018 - AJOB Empirical Bioethics 9 (2):82-90.
    Download  
     
    Export citation  
     
    Bookmark   5 citations  
  • Tracking the Variability of Authority and Power in the Physician-Patient Relationship.L. B. McCullough - 2009 - Journal of Medicine and Philosophy 34 (1):1-5.
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • The Ethics of Human Embryo Editing via CRISPR-Cas9 Technology: A Systematic Review of Ethical Arguments, Reasons, and Concerns.Lindsay Wiley, Mattison Cheek, Emily LaFar, Xiaolu Ma, Justin Sekowski, Nikki Tanguturi & Ana Iltis - forthcoming - HEC Forum:1-37.
    The possibility of editing the genomes of human embryos has generated significant discussion and interest as a matter of science and ethics. While it holds significant promise to prevent or treat disease, research on and potential clinical applications of human embryo editing also raise ethical, regulatory, and safety concerns. This systematic review included 223 publications to identify the ethical arguments, reasons, and concerns that have been offered for and against the editing of human embryos using CRISPR-Cas9 technology. We identified six (...)
    Download  
     
    Export citation  
     
    Bookmark